(Q34204347)

31 July 2017

1 reference

title

Novel treatments for bipolar disorder (English)

1 reference

31 July 2017

1 reference

C L Bowden

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

661-671

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Relapse and impairment in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Depression during mania. Treatment response to lithium or divalproex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Olanzapine-induced glucose dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Carbamazepine but not valproate induces bupropion metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Behavioral family treatment for patients with bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Lithium use and discontinuation in a health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.661

10.1517/13543784.10.4.661

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference